QLT has signed an exclusive option agreement with Mati Therapeutics for its punctal plug delivery system, which delivers drugs to the surface of the eye through the tear film.
QLT's new board revealed a multi-pronged effort that will reduce overhead costs and narrow the focus of the Vancouver-based eye drug specialist. And the biotech outfit's Punctal Plug Delivery System failed to make the cut.
The struggling Canadian biotech QLT is bidding its CEO goodbye along with 146 staffers as it pushes ahead toward critical pivotal studies on an experimental therapy.
This year we're naming Fierce 's 5 Drug Delivery Companies to Watch. All are making their mark by bringing drug delivery technology into everyday medical device and pharmaceutical use.
Tear duct plugs to deliver eye drugs face some challenges, such as keeping the tiny devices in place to release treatments. QLT ($QLTI), the Canadian eye drug specialist, has been on pushing ahead
Vancouver-based QLT ($QLTI), a developer of plugs inserted at the opening of the tear ducts to deliver eye treatments, is reporting that its latanoprost punctal plug delivery system is certainly...
Canada's QLT has sold its subsidiary QLT USA to Tolmar Holdings, a Colorado-based private pharma company, for $230 million. QLT USA's lead asset is Eligard, a line of products for prostate cancer. A
Shares of QLT rocketed up 55 percent in a tense market yesterday after the biotech finished a lengthy task in persuading the FDA that a blood test should not be required before doctors prescribe its
> Sanofi-Aventis has set up a small executive committee to set strategy, allocate resources and oversee company management, according to anonymous sources who talked to APM Europe. The idea is to
The board at Canada's QLT has decided to put itself up for sale after concluding that its business plan won't work. The announcement comes after sales of Visudyne, an eye therapy developed by QLTs,